E Fund Management Co. Ltd. Takes Position in Oruka Therapeutics, Inc. $ORKA

E Fund Management Co. Ltd. purchased a new position in shares of Oruka Therapeutics, Inc. (NASDAQ:ORKA) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 6,079 shares of the company’s stock, valued at approximately $579,000.

Other hedge funds have also recently modified their holdings of the company. BlackRock Inc. purchased a new position in Oruka Therapeutics in the 2nd quarter valued at $474,916,000. Viking Global Investors LP purchased a new position in Oruka Therapeutics during the 3rd quarter worth $51,280,000. Deep Track Capital LP lifted its stake in shares of Oruka Therapeutics by 38.4% in the 3rd quarter. Deep Track Capital LP now owns 2,654,781 shares of the company’s stock worth $51,051,000 after acquiring an additional 735,983 shares during the period. Vanguard Group Inc. lifted its stake in shares of Oruka Therapeutics by 38.1% in the 4th quarter. Vanguard Group Inc. now owns 2,453,530 shares of the company’s stock worth $74,366,000 after acquiring an additional 676,865 shares during the period. Finally, RTW Investments LP boosted its holdings in shares of Oruka Therapeutics by 5.8% in the fourth quarter. RTW Investments LP now owns 2,058,148 shares of the company’s stock valued at $62,382,000 after acquiring an additional 112,499 shares in the last quarter. 56.44% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Oruka Therapeutics

In other news, Director Carl Dambkowski sold 12,583 shares of the business’s stock in a transaction that occurred on Friday, June 12th. The stock was sold at an average price of $70.11, for a total transaction of $882,194.13. Following the sale, the director owned 38,743 shares of the company’s stock, valued at $2,716,271.73. The trade was a 24.52% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Lawrence Otto Klein sold 1,729 shares of the company’s stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $69.69, for a total value of $120,494.01. Following the completion of the sale, the chief executive officer owned 925,580 shares in the company, valued at approximately $64,503,670.20. This represents a 0.19% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 83,116 shares of company stock valued at $6,636,533 in the last 90 days. Insiders own 23.49% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on ORKA. Barclays boosted their price target on shares of Oruka Therapeutics from $78.00 to $160.00 and gave the stock an “overweight” rating in a research note on Monday, April 27th. Guggenheim reaffirmed a “buy” rating and issued a $200.00 price objective on shares of Oruka Therapeutics in a report on Tuesday, August 11th. Piper Sandler reiterated an “overweight” rating and set a $180.00 target price on shares of Oruka Therapeutics in a research report on Tuesday, June 2nd. Leerink Partners set a $120.00 target price on Oruka Therapeutics in a research report on Thursday, April 30th. Finally, Wall Street Zen downgraded Oruka Therapeutics from a “hold” rating to a “sell” rating in a research note on Sunday, August 16th. Ten research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Oruka Therapeutics has an average rating of “Moderate Buy” and an average price target of $134.30.

Oruka Therapeutics Stock Down 4.4%

NASDAQ:ORKA opened at $104.86 on Friday. Oruka Therapeutics, Inc. has a fifty-two week low of $14.10 and a fifty-two week high of $115.51. The stock has a market cap of $6.94 billion, a PE ratio of -51.66 and a beta of -0.34. The firm’s fifty day simple moving average is $91.06 and its 200-day simple moving average is $64.93.

Oruka Therapeutics (NASDAQ:ORKA) last announced its quarterly earnings results on Monday, August 10th. The company reported ($0.55) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.04). Equities analysts anticipate that Oruka Therapeutics, Inc. will post -2.27 earnings per share for the current year.

About Oruka Therapeutics

Oruka Therapeutics, Inc is a clinical?stage biopharmaceutical company focused on the development of novel peptide?based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell?permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.